These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9111610)

  • 1. Phase II studies on prostate cancer.
    Schröder FH; Norming U; Blumenstein BA; Busch C; Van Glabbeke M; Høisaeter PA; Johansson JE; Tribukait B
    Urology; 1997 Apr; 49(4A Suppl):3-14. PubMed ID: 9111610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
    Bubley GJ; Carducci M; Dahut W; Dawson N; Daliani D; Eisenberger M; Figg WD; Freidlin B; Halabi S; Hudes G; Hussain M; Kaplan R; Myers C; Oh W; Petrylak DP; Reed E; Roth B; Sartor O; Scher H; Simons J; Sinibaldi V; Small EJ; Smith MR; Trump DL; Wilding G
    J Clin Oncol; 1999 Nov; 17(11):3461-7. PubMed ID: 10550143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.
    Fazzari M; Heller G; Scher HI
    Control Clin Trials; 2000 Aug; 21(4):360-8. PubMed ID: 10913810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment response criteria for prostatic cancer.
    Schroeder FH
    Prostate; 1984; 5(2):181-91. PubMed ID: 6369278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
    Nair B; Wilt T; MacDonald R; Rutks I
    Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and follow-up of patients with N1-3 M0 or NXM1 prostate cancer in phase III trials.
    Hall R; Hedlund PO; Ackermann R; Bruchovsky N; Dalesio O; Debruyne F; Murphy GP; Parmar MK; Pavone-Macaluso M; Ruutu M; Smith P
    Urology; 1997 Apr; 49(4A Suppl):39-45. PubMed ID: 9111613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Picking the winners in a sea of plenty.
    Scher HI; Heller G
    Clin Cancer Res; 2002 Feb; 8(2):400-4. PubMed ID: 11839655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multistage designs for phase II clinical trials: statistical issues in cancer research.
    Kramar A; Potvin D; Hill C
    Br J Cancer; 1996 Oct; 74(8):1317-20. PubMed ID: 8883425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
    Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
    J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report.
    Martin PJ; Weisdorf D; Przepiorka D; Hirschfeld S; Farrell A; Rizzo JD; Foley R; Socie G; Carter S; Couriel D; Schultz KR; Flowers ME; Filipovich AH; Saliba R; Vogelsang GB; Pavletic SZ; Lee SJ;
    Biol Blood Marrow Transplant; 2006 May; 12(5):491-505. PubMed ID: 16635784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexible designs for phase II comparative clinical trials involving two response variables.
    Bersimis S; Sachlas A; Papaioannou T
    Stat Med; 2015 Jan; 34(2):197-214. PubMed ID: 25274584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Criteria and endpoints in advanced prostate cancer].
    Piedbois P; Buyse M
    Bull Cancer; 2012 Jul; 99 Suppl 1():S16-20. PubMed ID: 22511187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designs for phase II trials allowing for a trade-off between response and toxicity.
    Conaway MR; Petroni GR
    Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.
    Filion M; Forget G; Brochu O; Provencher L; Desbiens C; Doyle C; Poirier B; DuRocher M; Camden S; Lemieux J
    Clin Trials; 2012 Oct; 9(5):652-9. PubMed ID: 23060323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
    Lieberman R
    Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.